CORT vs. COR

Last updated Jun 9, 2026

CORT (Corcept Therapeutics Incorporated) and COR (Cencora Inc.) are both stocks. Both are in the Healthcare sector — CORT in Biotechnology, COR in Medical Distribution. Over the past 10 years, CORT returned 29.33%/yr vs 17.00%/yr for COR. At a 0.15 correlation, their price movements are largely independent.

Performance

CORT vs. COR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Corcept Therapeutics Incorporated (CORT) and Cencora Inc. (COR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CORT achieves a 110.72% return, which is significantly higher than COR's -18.53% return. Over the past 10 years, CORT has outperformed COR with an annualized return of 29.33%, while COR has yielded a comparatively lower 17.00% annualized return.

CORT

• 1D: 0.98%
• 1M: 40.26%
• YTD: 110.72%
• 6M: -11.63%
• 1Y: 5.36%
• 3Y*: 46.50%
• 5Y*: 27.35%
• 10Y*: 29.33%

COR

• 1D: -0.35%
• 1M: 5.22%
• YTD: -18.53%
• 6M: -18.54%
• 1Y: -4.43%
• 3Y*: 16.42%
• 5Y*: 20.49%
• 10Y*: 17.00%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CORT vs. COR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CORT Corcept Therapeutics Incorporated	110.72%	-30.94%	55.14%	59.92%	2.58%	-24.31%	116.20%	-9.43%	-26.02%	148.76%
COR Cencora Inc.	-18.53%	51.48%	10.37%	25.33%	26.26%	44.09%	23.37%	23.51%	-17.57%	19.51%

Correlation

The correlation between CORT and COR is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.12
Correlation (3Y) Calculated over the trailing 3-year period	0.05
Correlation (5Y) Calculated over the trailing 5-year period	0.09
Correlation (10Y) Calculated over the trailing 10-year period	0.17
Correlation (All Time) Calculated using the full available price history since Apr 14, 2004	0.15

The correlation between CORT and COR shifts across timeframes, from 0.05 (3 years) to 0.17 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap CORT : $7.66B COR : $53.55B
EPS CORT : $0.41 COR : $13.07
PE Ratio CORT : 178.81 COR : 20.97
PEG Ratio CORT : 89.07 COR : 9.96
PS Ratio CORT : 11.07 COR : 0.16
PB Ratio CORT : 12.00 COR : 15.76
Total Revenue (TTM) CORT : $769.10M COR : $328.68B
Gross Profit (TTM) CORT : $755.64M COR : $11.66B
EBITDA (TTM) CORT : $3.66M COR : $3.64B

Return for Risk

CORT vs. COR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CORT

CORT Risk / Return Rank: 47
CORT Sharpe Ratio Rank: 44
CORT Sortino Ratio Rank: 47
CORT Omega Ratio Rank: 56
CORT Calmar Ratio Rank: 44
CORT Martin Ratio Rank: 44

COR

COR Risk / Return Rank: 34
COR Sharpe Ratio Rank: 36
COR Sortino Ratio Rank: 31
COR Omega Ratio Rank: 31
COR Calmar Ratio Rank: 38
COR Martin Ratio Rank: 35

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CORT vs. COR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Corcept Therapeutics Incorporated (CORT) and Cencora Inc. (COR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CORT	COR	Difference
Sharpe ratio: Return per unit of total volatility	0.07	-0.15	+0.22
Sortino ratio: Return per unit of downside risk	0.66	0.01	+0.65
Omega ratio: Gain probability vs. loss probability	1.14	1.00	+0.14
Calmar ratio: Return relative to maximum drawdown	0.08	-0.14	+0.22
Martin ratio: Return relative to average drawdown	0.15	-0.39	+0.55
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CORT vs. COR - Sharpe Ratio Comparison

The current CORT Sharpe Ratio is 0.07, which is higher than the COR Sharpe Ratio of -0.15. The chart below compares the historical Sharpe Ratios of CORT and COR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	CORT	COR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.07	-0.15	+0.22
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.37	0.92	-0.55
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.44	0.62	-0.18
Sharpe Ratio (All Time) Calculated using the full available price history	0.11	0.54	-0.43

Drawdowns

CORT vs. COR - Drawdown Comparison

The maximum CORT drawdown since its inception was -94.28%, which is greater than COR's maximum drawdown of -71.01%. Use the drawdown chart below to compare losses from any high point for CORT and COR.

Drawdown Indicators

	CORT	COR	Difference
Max Drawdown Largest peak-to-trough decline	-94.28%	-71.01%	-23.27%
Max Drawdown (1Y) Largest decline over 1 year	-64.40%	-32.44%	-31.96%
Max Drawdown (3Y) Largest decline over 3 years	-71.85%	-32.44%	-39.41%
Max Drawdown (5Y) Largest decline over 5 years	-71.85%	-32.44%	-39.41%
Max Drawdown (10Y) Largest decline over 10 years	-71.85%	-32.44%	-39.41%
Current Drawdown Current decline from peak	-35.80%	-26.57%	-9.23%
Average Drawdown Average peak-to-trough decline	-53.44%	-13.62%	-39.82%
Ulcer Index Depth and duration of drawdowns from previous peaks	35.34%	11.26%	+24.08%

Volatility

CORT vs. COR - Volatility Comparison

Corcept Therapeutics Incorporated (CORT) has a higher volatility of 16.41% compared to Cencora Inc. (COR) at 7.05%. This indicates that CORT's price experiences larger fluctuations and is considered to be riskier than COR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CORT	COR	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.41%	7.05%	+9.36%
Volatility (6M) Calculated over the trailing 6-month period	85.07%	26.87%	+58.20%
Volatility (1Y) Calculated over the trailing 1-year period	76.73%	30.25%	+46.48%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	74.52%	22.34%	+52.18%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	67.22%	27.49%	+39.73%

Dividends

CORT vs. COR - Dividend Comparison

CORT has not paid dividends to shareholders, while COR's dividend yield for the trailing twelve months is around 0.86%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
COR Cencora Inc.	0.86%	0.67%	0.93%	0.96%	1.13%	5.13%	6.74%	7.48%	2.07%	1.61%	1.77%	1.17%
CORT Corcept Therapeutics Incorporated	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

CORT vs. COR - Profitability Comparison

The chart below illustrates the profitability comparison between Corcept Therapeutics Incorporated and Cencora Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

CORT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a gross profit of 162.02M and revenue of 164.90M. Therefore, the gross margin over that period was 98.3%.

COR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cencora Inc. reported a gross profit of 3.59B and revenue of 78.36B. Therefore, the gross margin over that period was 4.6%.

CORT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported an operating income of -49.60M and revenue of 164.90M, resulting in an operating margin of -30.1%.

COR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cencora Inc. reported an operating income of 1.14B and revenue of 78.36B, resulting in an operating margin of 1.5%.

CORT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a net income of -31.20M and revenue of 164.90M, resulting in a net margin of -18.9%.

COR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cencora Inc. reported a net income of 1.64B and revenue of 78.36B, resulting in a net margin of 2.1%.

Frequently Asked Questions

Can I hold both CORT and COR in my portfolio?

CORT and COR have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, CORT or COR?

CORT has higher volatility (16.41%) compared to COR (7.05%). In terms of maximum drawdown, CORT dropped -94.28% vs COR's -71.01%.

Which has better risk-adjusted returns?

CORT currently has the higher Sharpe Ratio (0.07 vs -0.15), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.